Cardiorenal Research Unit, Department of Clinical and Experimental Medicine, University of Parma Medical School, Via Gramsci 14, 43126 Parma, Italy.
Int J Cardiol. 2013 Oct 9;168(4):3334-9. doi: 10.1016/j.ijcard.2013.04.039. Epub 2013 Apr 25.
An accurate prognosis prediction represents a key element in chronic heart failure (CHF) management. Seattle Heart Failure Model (SHFM) prognostic power, a validated risk score for predicting mortality in CHF, is improved by adding B-type natriuretic peptide (BNP). We evaluated in a prospective study the incremental value of several biomarkers, linked to different biological domains, on death risk prediction of BNP-added SHFM.
Troponin I (cTnI), norepinephrine, plasma renin activity, aldosterone, high sensitivity-C reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), interleukin 2 soluble receptor, leptin, prealbumin, free malondialdehyde, and 15-F2t-isoprostane were measured in plasma from 142 consecutive ambulatory, non-diabetic stable CHF (mean NYHA-class 2.6) patients (mean age 75±8years). Calibration, discrimination, and risk reclassification of BNP-added SHFM were evaluated after individual biomarker addition.
Individual addition of biomarkers to BNP-added SHFM did not improve death prediction, except for prealbumin (HR 0.49 CI: (0.31-0.76) p=0.002) and cTnI (HR 2.03 CI: (1.20-3.45) p=0.009). In fact, with respect to BNP-added SHFM (Harrell's C-statistic 0.702), prealbumin emerged as a stronger predictor of death showing the highest improvement in model discrimination (+0.021, p=0.033) and only a trend was observed for cTn I (+0.023, p=0.063). These biomarkers showed also the best reclassification statistic (Integrated Discrimination Improvement-IDI) at 1-year (IDI: cTnI, p=0.002; prealbumin, p=0.020), 2-years (IDI: cTnI, p=0.018; prealbumin: p=0.006) and 3-years of follow-up (IDI: cTnI p=0.024; prealbumin: p=0.012).
Individual addition of prealbumin allows a more accurate prediction of mortality of BNP enriched SHFM in ambulatory elderly CHF suggesting its potential use in identifying those at high-risk that need nutritional surveillance.
准确的预后预测是慢性心力衰竭(CHF)管理的关键要素。西雅图心力衰竭模型(SHFM)的预后能力是预测心力衰竭患者死亡率的经过验证的风险评分,通过添加 B 型利钠肽(BNP)可以提高其预测能力。我们在一项前瞻性研究中评估了几种生物标志物的增量价值,这些标志物与不同的生物学领域相关联,可用于预测 BNP 加 SHFM 死亡风险。
从 142 例连续的、非糖尿病的稳定 CHF(平均 NYHA 分级 2.6)患者(平均年龄 75±8 岁)的血浆中测量了肌钙蛋白 I(cTnI)、去甲肾上腺素、血浆肾素活性、醛固酮、高敏 C 反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素 6(IL-6)、白细胞介素 2 可溶性受体、瘦素、前白蛋白、游离丙二醛和 15-F2t-异前列腺素。在单独添加生物标志物后,评估了 BNP 加 SHFM 的校准、区分和风险再分类。
除了前白蛋白(HR 0.49,CI:(0.31-0.76),p=0.002)和 cTnI(HR 2.03,CI:(1.20-3.45),p=0.009)外,其他生物标志物的单独添加并不能改善死亡预测。实际上,与 BNP 加 SHFM(Harrell 的 C 统计量为 0.702)相比,前白蛋白作为死亡的更强预测因子出现,显示出对模型区分度的最高改善(+0.021,p=0.033),而 cTnI 仅呈趋势(+0.023,p=0.063)。这些生物标志物在 1 年(IDI:cTnI,p=0.002;前白蛋白,p=0.020)、2 年(IDI:cTnI,p=0.018;前白蛋白,p=0.006)和 3 年随访(IDI:cTnI,p=0.024;前白蛋白,p=0.012)时的再分类统计数据(综合鉴别改善-ID)也显示出最佳效果。
在非卧床老年 CHF 患者中,前白蛋白的单独添加可更准确地预测 BNP 富集 SHFM 的死亡率,提示其在识别高危患者并进行营养监测方面具有潜在应用价值。